# A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

Source: https://onco.cc/trials/nct06911827/  
OnCo record `nct06911827` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of QL2107 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients is a phase 1/2 interventional study registered as NCT06911827 by Qilu Pharmaceutical Co., Ltd., with 149 participants planned, started 2025-05-09 and due to reach its primary completion in 2027-12. Interventions recorded: QLP2117 and QL2107.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06911827
- Phase: 1/2
- Setting: A Phase Ib/II Open-Label, Dose-Escalation and Dose-expansion Clinical Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 149

## Sources

- ClinicalTrials.gov NCT06911827: https://clinicaltrials.gov/study/NCT06911827

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [QL2107](https://onco.cc/drugs/ql2107/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06911827.json